Skip to main content
    E

    Eli Lilly and Company (LLY)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE

    $1433.55
    -9.95 (-0.69%)

    Market Cap: $1.29T

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Eli Lilly and Company (LLY) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Eli Lilly and Company (LLY) trades at 44.9x trailing earnings and 14.8x sales. Its P/E of 44.9x is below its 5-year median of 46.0x. Its forward P/E is 29.0x. The median P/E across 9 similar companies is 19.9x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 54.8% higher over the next year. Its free cash flow yield is 1.5%.

    MultipleValue
    P/E (trailing)44.9x
    Forward P/E29.0x
    Price to sales14.8x
    Price to book31.8x
    EV/EBITDA35.8x
    Price to FCF65.0x
    EV/FCF67.3x
    PEG1.3
    FCF yield1.5%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/E is 48.2% above 30.3x, its P/S is 78.3% above 8.3x and its P/B is 0.3% above 31.7x.

    MultipleCurrent5-year median10-year median
    P/E44.9x46.0x30.3x
    P/S14.8x13.6x8.3x
    P/B31.8x35.4x31.7x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/E ranged from 19.7x in 2017 to 92.2x in 2023.

    Year endPriceP/EP/SP/B
    2025$1,074.6844.4x14.8x36.4x
    2024$772.0059.4x15.5x49.1x
    2023$582.9292.2x15.4x48.9x
    2022$365.8446.1x11.7x32.6x
    2021$276.2233.8x9.0x29.3x
    2020$168.8421.3x6.3x28.6x
    2019$131.4321.8x5.5x48.3x
    2018$115.7220.8x5.6x12.4x
    2017$84.4619.7x4.5x7.7x
    2016$73.5520.9x3.7x5.8x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About LLY

    What is LLY's forward P/E ratio?

    Eli Lilly and Company has a forward P/E ratio of 29.0x.

    Is LLY stock overvalued?

    GNG's valuation label for LLY is Undervalued. Its P/E of 44.9x compares with a median of 19.9x across 9 similar companies.

    What is LLY's price to sales ratio?

    Eli Lilly and Company has a price to sales ratio of 14.8x.

    What is Eli Lilly and Company's average P/E ratio over 5 years?

    Eli Lilly and Company's median P/E over the last 5 years is 46.0x, from 60 month-end values through Oct 2026.

    What is LLY's PEG ratio?

    Eli Lilly and Company has a PEG ratio of 1.3.